• Edesa Biotech posted a net loss of $4.2 million, or $0.49 per share, for the quarter ended March 31, 2026, widening from a $1.6 million loss a year earlier.
• Operating expenses climbed to $4.3 million from $1.6 million, led by R&D spending rising to $2.77 million from $484,306.
• Cash and cash equivalents were $10 million at March 31, 2026, with working capital of $8.2 million.
• EB06 vitiligo program advanced with Health Canada clearance for a Phase 2 proof-of-concept study; site activation and patient enrollment expected by midyear 2026, subject to regulatory approval.
• Paridiprubart Phase 3 ARDS study data showed a statistically significant reduction in 28-day mortality across a 278-patient population; candidate is also in a U.S. government-funded ARDS platform study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edesa Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-003433), on May 14, 2026, and is solely responsible for the information contained therein.